Jensen BV - Search Results

1

Genomic landscape of treatment refractory metastatic colorectal cancer.

Eefsen RL, Simonsen KS, Grundtvig P, Klarskov L, Chen IM, Høgdall D, Jensen BV, Lorentzen T, Poulsen TS, Theile S, Nielsen D, Høgdall E. Eefsen RL, et al. Among authors: jensen bv. Acta Oncol. 2021 Dec;60(12):1621-1628. doi: 10.1080/0284186X.2021.1984575. Epub 2021 Oct 4. Acta Oncol. 2021. PMID: 34606390

2

Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer.

Ryberg M, Nielsen D, Skovsgaard T, Hansen J, Jensen BV, Dombernowsky P. Ryberg M, et al. Among authors: jensen bv. J Clin Oncol. 1998 Nov;16(11):3502-8. doi: 10.1200/JCO.1998.16.11.3502. J Clin Oncol. 1998. PMID: 9817267

3

Angiotensin converting enzyme inhibitors for cancer treatment?

Lindberg H, Nielsen D, Jensen BV, Eriksen J, Skovsgaard T. Lindberg H, et al. Among authors: jensen bv. Acta Oncol. 2004;43(2):142-52. doi: 10.1080/02841860310022346. Acta Oncol. 2004. PMID: 15163162 Review.

4

Serum YKL-40, a new prognostic biomarker in cancer patients?

Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA. Johansen JS, et al. Among authors: jensen bv. Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):194-202. doi: 10.1158/1055-9965.EPI-05-0011. Cancer Epidemiol Biomarkers Prev. 2006. PMID: 16492905 Review.

5

Re-treatment with cetuximab in patients with severe hypersensitivity reactions to cetuximab. Two case reports.

Nielsen DL, Pfeiffer P, Jensen BV. Nielsen DL, et al. Among authors: jensen bv. Acta Oncol. 2006;45(8):1137-8. doi: 10.1080/02841860600871764. Acta Oncol. 2006. PMID: 17118853 No abstract available.

6

Phase I study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first line therapy in patients with non-resectable gastric cancer.

Dupont J, Jensen HA, Jensen BV, Pfeiffer P. Dupont J, et al. Among authors: jensen bv, jensen ha. Acta Oncol. 2007;46(3):330-5. doi: 10.1080/02841860600949578. Acta Oncol. 2007. PMID: 17450468 Clinical Trial.

7

Anthracycline-induced chronic cardiotoxicity and heart failure.

Appel JM, Nielsen D, Zerahn B, Jensen BV, Skagen K. Appel JM, et al. Among authors: jensen bv. Acta Oncol. 2007;46(5):576-80. doi: 10.1080/02841860601156165. Acta Oncol. 2007. PMID: 17562433 Review.

8

Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil.

Pfeiffer P, Nielsen D, Yilmaz M, Iversen A, Vejlø C, Jensen BV. Pfeiffer P, et al. Among authors: jensen bv. Acta Oncol. 2007;46(5):697-701. doi: 10.1080/02841860601009455. Acta Oncol. 2007. PMID: 17562448

9

Six cases of treatment with panitumumab in patients with severe hypersensitivity reactions to cetuximab.

Nielsen DL, Pfeiffer P, Jensen BV. Nielsen DL, et al. Among authors: jensen bv. Ann Oncol. 2009 Apr;20(4):798. doi: 10.1093/annonc/mdp040. Epub 2009 Mar 2. Ann Oncol. 2009. PMID: 19254943 Free article. No abstract available.

10

Systolic versus diastolic cardiac function variables during epirubicin treatment for breast cancer.

Appel JM, Jensen BV, Nielsen DL, Ryberg M, Zerahn B. Appel JM, et al. Among authors: jensen bv. Int J Cardiovasc Imaging. 2010 Feb;26(2):217-23. doi: 10.1007/s10554-009-9518-2. Epub 2009 Oct 13. Int J Cardiovasc Imaging. 2010. PMID: 19823942

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

122 results

Search Page